Pfizer and BioNTech's COVID-19 vaccine targeting Omicron BA.4 and BA.5 has been recommended for authorisation by the EMA's human medicines committee, shortly after the panel gave its blessing to ...

Pfizer and partner BioNTech have started their clinical trial of a new version of their COVID-19 vaccine that has been specifically designed to protect against the Omicron variant. The trial in ...

The shot was developed by Pfizer and targets the JN.1 sub-variant of Omicron. This is now the fifth iteration of the COVID vaccines, which have been updated regularly to keep up with the rapidly ...

Historically, COVID-19 symptoms have been fevers or chills, cough, shortness of breath, cough, congestion or a runny nose, ...